MicroStockProfit.com announces an investment report featuring ULURU Inc. (AMEX:ULU). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
ULURU Inc. (ULU) is a diversified specialty pharmaceutical company. The Company is focused in the developing and commercializing a range of wound care and muco-adhesive film products based on its Nanoflex and OraDisc drug delivery technologies. ULU's Nanoflex technology system has at its core a system of hydrogel-like nanoparticles composed of a polymer used in manufacturing contact lenses and other U.S. Food and Drug Administration (FDA)-approved implants. Utilizing its Nanoflex technology, it has developed three separate development platforms from the system: Nanoflex Powder, Nanoflex Gel and Nanoflex Injectable Liquid. Its Nanoflex Powder is composed of hydrogel particle flakes that aggregate immediately and irreversibly upon contact with physiological fluid, such as wound exudate, forming a nonresorbable film.
Message Board Search for ULU: http://www.boardcentral.com/boards/ULU
In the report, the analyst notes:
"For the first quarter of 2010, ULU reported a net loss of $1.3 million, or $0.02 per share, compared with a net loss of $3.1 million, or $0.05 per share, for the same period last year. At March 31, 2010, the Company held cash and cash equivalents of $2.2 million, compared with $1.9 million at December 31, 2009.
"ULU announced recently that six posters detailing clinical experience using Altrazeal™ Transforming Powder Dressing will be presented at the 2010 Joint Conference of the Wound Ostomy and Continence Nurses Society (WOCN) and World Council of Enterostomal Therapists (WCET) on June 14-16 in Phoenix, Arizona."
To read the entire report visit: www.microstockprofit.com/lp/ULU
SolasCure publishes phase IIa clinical trial report in leading wound care journal